Safety of DNP007 in Healthy Subjects

PHASE1RecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

June 10, 2024

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Liver Transplant RejectionLiver Transplant; ComplicationsSteatohepatitis, Nonalcoholic
Interventions
DRUG

DNP007

DNP007 is a therapeutic agent that can replace calcineurin inhibitor (CNI), which is a representative factor that can be used as an adhesive for extrahepatic long-term survival patches such as after liver transplantation in patients with liver disease and hepatocellular carcinoma, adult metabolic status, neoplasms, etc. , an anti-ICAM-1 mouse monoclonal minority, is a humanized Fab region that humanizes MD-3 and the Fc region of human IgG1, separated by translational engineering.

Trial Locations (1)

03080

RECRUITING

Seoul National University Hospital, Seoul

All Listed Sponsors
lead

Seoul National University Hospital

OTHER